Carrillo ER, Sánchez ZMJ

Language: Spanish
References: 77
Page: 296-312
PDF size: 229.46 Kb.

ABSTRACT

The cardiovascular system delivers oxygen and nutrients to the skeletal muscles. To do so, the function of the heart pump is to integrate and couple the body’s requirements. Otherwise, several ultrastructural alterations may occur to compensate for the loss of oxygen. Heart failure is a complex clinical syndrome involving activation of multiple several neurohumoral pathways; it includes: the renin-angiotensin-aldosterone system, sympathetic system, endothelium, and diverse cytokines. The heart’s lack of pumping ability allowed the use of drugs that increase strength of contraction of the heart muscle in important sites of neurohumoral interaction, but medications cannot stop the progression of the disease. Current treatment protocols focus on the modulation of signs that activate the processes that control cardiac remodeling, such as fibrosis and hypertrophy. However, such treatments are not aimed at relieving symptoms, since most patients are in late stages of the illness.

REFERENCES

1. Karman B, Mahon N, McKenna WJ, et al. The pathophysiology of advanced heart failure. Am Heart J 1998;135:S216-30.

2. Francis GS. Pathophysiology of chronic heart failure. Am J Med 2001;110:S7A.

3. Pedemonte SF. Nuevos inotrópicos. Rev Col Anest 1996;24:29-32.

4. Endoh M. Mechanisms of action of novel cardiotonic agents. J Cardiovasc Pharmacol 2002;40:323-38.

5. Braunwald E, Mock MB, Watson J. Congestive heart failure: current research and clinical application. New York: Grune and Straton, 1982.

6. Braunwald E, Ross J Jr, Sonnenblick EH. Mechanisms of the contraction of the normal and failing heart. 2nd ed. Boston: Little, Brown and Co., 1976.

7. Crozartier B, Hittinger L. Mechanical adaptation to chronic pressure overload. Eur Heart J 1998;9(Suppl E):7-11.

8. Dzau VJ. Autocrine and paracrine mechanisms in the pathophysiology of heart failure. Am J Cardiol 1992;70:4AC.

9. Thomas JA. Plasma norepinephrine in congestive heart failure. Am J Cardiol 1978:41:233.

10. Francis GS, Goldsmith SR, Levine TB, et al. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984;101:370.

11. Pery SV. The regulation of contractile activity in muscle. Biochem Soc Trans 1979;7:593-617.

12. Wang K, Ramirez-Mitchell R, Palter D, et al. Titin is an extraordinarily long, flexible, and slender myofibrillar protein. Proc Natl Acad Sci USA 1984;81:3685-9.

13. Hein S. Altered expression of titin and contractile proteins in failing human myocardium. J Mol Cell Cardiol 1994;26:1291-306.

14. Fisher J, Smith CA, Thoden J, et al. Structural studies of myosin: nucleotide complexes: a revised model for the molecular basis of muscle contraction. Biophys J 1995;68:19-28.

15. Hofmann PA. Evidence for a force-dependent component of calcium binding to cardiac troponin C. Am J Physiol 1987;253:541-6.

16. Fabiato A. Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum. Am J Physiol 1983;254:1-14.

17. Berrigde MJ. Inositol trisphosphate and calcium signaling. Nature 1993;361:315-25.

18. Wagenknecht T, Grassucci R, Frank J, et al. Three-dimensional architecture of the calcium channel/foot structure of sarcoplasmic reticulum. Nature 1989;338:167-70.

19. Go LO, Moschella MC, Watras J, et al. Differential regulation of two types of intracellular calcium release channels during end-stage human heart failure. Circulation 1994;90: Abs I-L.

20. Blomm A, Miller H. Role of cytokines in heart failure. Am Heart J 2000;135:181-6.

21. Fang ZY, Marwick TH. Vascular dysfunction and heart failure: epiphenomenon or etiologic agent? Am Heart J 2002;143:383-90.

22. Felman MA, Kadokami T, Higuichi Y, et al. The role of anticytokine therapy in heart failure. Recent lessons from preclinical and clinical trials. Med Clin North Am 2003;87(2):419-40.

23. Ronco JJ. Anti-inflammatory effects of inotropic drugs in the treatment of septic shock; another piece the puzzle. Crit Care Med 2001;29:1837-8.

24. Mercadier JJ. Altered sarcoplasmic reticulum Ca++- ATPase gene expression in the human ventricule during end-stage heart failure. J Clin Invest 1990;85:305.

25. Frey NM, McKinsey TA, Olson EN, et al. Decoding calcium signals involved in cardiac growth and function. Nat Med 2002;6:1221-7.

26. Hajjar RJ, del Monte F, Matsui T, et al. Prospects for gene therapy for heart failure. Circ Res 2002;86:616-21.

27. Brittsan AG, Kranias EG. Phospholamban and cardiac contractile function. J Mol Cell Cardiol 2000;32(12):2131-9.

28. Lynne W, Stevenson MD. Clinical use of inotropic therapy for heart failure: looking backward or forward? Circulation 2003;108:367-72.

29. Felker GM, Adams KF Jr, Konstam MA, et al. The problem of decompensated heart failure: nomenclature, classification, and risk stratification. Am Heart J 2003;145:S18-25.

30. Felker GM, O’Connor CM. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J 2001;142:393-401.

31. López-Sendon JL, Tamargo J. Perspectivas futuras de aproximación terapéutica al paciente con insuficiencia cardiaca. Monocardio 2002;2:99-108.

32. Cuesta TMT, Martínez de la Gándara M. Nuevos principios activos. Información terapéutica del Sistema Nacional de Salud 2002;26:158-62.

33. Simdax. Ficha técnica de la especialidad. Agencia Española del Medicamento (AGEMED). Ministerio de Sanidad y Consumo, 2002.

34. Figgitt DP, Gillies PS, Goa KL, et al. Levosimendan. Drugs 2001;61(5):613-27.

35. Lehtonen L. Levosimendan: a promising agent for the treatment of hospitalized patients with decompensated heart failure. Curr Cardiol Rep 2002;2:233-43.

36. Lehtonen L. Levosimendan: un calciosensibilizante parenteral con efectos vasodilatadores adicionales. Expert Opin Investing Drugs 2001;10:955-71.

37. Haikala H. Cardiac troponin C as a target protein a for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995;27:1859-66.

38. Levijoki J, Pollesello P, Kaivola J, et al. Further evidence for the cardiac troponin C mediated calcium sensitization by levosimendan structure-response and binding analysis with analog of levosimendan. J Mol Cell Cardiol 2002;32:479-91.

39. Anders O. Effect of levosimendan a novel inotropic calcium sensitizing drugs in experimental septic shock. Crit Care Med 2001;29:2185-93.

40. Parissis JT, , Antoniades C, et al. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 2004;93(10):1309-12.

41. Schwats SM. Cellular and molecular aspects of myocardium dysfunction. Crit Care Med 2001; 29.

42. Frishman WH. Advances in positive inotropic therapy: levosimendan. Crit Care Med 2003;31(9):2408-931.

43. Drugdez. Drug evaluation: levosimendan. Micromex. Healthcare series 2002;114.

44. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360(9328):196-202.

45. Moiseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002;23:1422-32.

46. Nieminen MS, Akkila J, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2002;36:1903-12.

47. Lilleberg J. Dose-range study of a new calcium sensitizer, levosimendan in patients with left ventricular dysfunction. J Cardiovasc Pharmacol 1995;26:S163-9.

48. Hosenpud JD. For the Oral Levosimendan Study Group: levosimendan a novel myofilament calcium sensitizer, allows weaning of parenteral inotropic therapy in patients with severe congestive heart failure. Am J Cardiol 1999;83:9(I)-11(I).

49. Baruch L, Patacsil P, Hameed A, et al. Pharmacodynamic effects of milrinone with and without a bolus loading infusion. Am Heart J 2001;141(2):266-73.

50. Colucci WS. Myocardial and vascular actions of milrinone. Eur Heart J 1989;10(Suppl C):32-38.

51. Givertz MM. Effects of bolus milrinone on hemodynamic variable and pulmonary vascular resistance in patients with severe left ventricular dysfunction. A rapid tests for reversibility of pulmonary hypertension. J Am Coll Cardiol 1996;28:1775-80.

52. Parker M. Effects of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study. N Engl J Med 1991;325:1468-75.

53. Feneck RO. Effects of variable dose milrinone in patients with low cardiac output after cardiac surgery. Am Heart J 1991;121:1995-9.

54. Karlsberg RP. Comparative efficacy of short-term intravenous infusions of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction. Milrinone-Dobutamine Study Group. Clin Cardiol 1996;19:21-30.

55. Lobato EB. Effects of milrinone versus epinephrine on grafted mammary artery flow after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2000;14:9-11.

56. Loh E. A randomized multicenter study comparing the efficacy and safety of intravenous milrinone and intravenous nitroglycerin in patients with advances heart failure. J Cardiac Fail 2001;7:114-21.

57. Silver MA. Outcomes of a prospective trial of intravenous milrinone for exacerbation of chronic heart failure (OPTIME_CHF) Investigators. JAMA 2002;87:1541-7.

58. Caldicott LD, Hawley K, Heppell R, Woodmansey PA, Channer KS. Intravenous enoximone or dobutamine for severe heart failure after acute myocardial infarction: a randomized double-blind trial. Eur Heart J 1993;14:696-700.

59. Cowley AJ. Treatment of severe heart failure: quantity or quality of life? A trial enoximone. Enoximone investigators. Br Heart J 1994;72:226:30.

60. Jondeau G, Dubourg O, Delorme G, et al. Oral enoximone as substitute for intravenous catecholamine support in end-stage congestive heart failure. Eur Heart J 1994;15:242-6.

61. Lowes BD, Higginbotham M, Petrovich L, et al. Low dose enoximone improves exercise capacity in chronic heart failure. J Am Coll Cardiol 2000;36:501-8.

62. Focaccio A, Peeters G, Movsesian M, et al. Mechanisms of action of OPC-8490 in human ventricular myocardium. Circulation 1996;93(4):817-25.

63. Scherrer-Crosbie M, Cocca-Spofford D, DiSalvo TG, et al. Effect of vesnarinone on cardiac function in patients with severe congestive heart failure. Am Heart J 1998;136:769-77.

64. Felman AM. Effects of vesnarinone on morbidity and mortality in patients with heart failure: Vesnarinone Study Group. N Engl J Med 1993;329:149-55.

65. Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med 1998;339:1810-6.

66. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339(5):321-8.

67. Rubattu S, Volpe M. The atrial natriuretic peptide: a changing view. J Hypertens 2001;19:1923-31.

68. Sagnella GA. Atrial natriuretic peptide mimetic and vasopeptidase inhibitors. Cardiovasc Res 2001;51:416-26.

69. Boomsma F. Plams A- and B- type natriuretic peptides: physiology, methodology and clinical use. Cardiovasc Res 2001;51:442-9.

70. Nicholl MG. The natriuretic peptide in heart failure. J Intern Med 1994;235:515-26.

71. Davison NC, Naas AA, Hanson JK, et al. Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am J Cardiol 1996;77(10):828-31.

72. Yoshimura M. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 1991;84:1581-8.

73. Holmes SJ, Espiner EA, Richards AM, et al. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 1993;76: 91-96.

74. Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction. Circulation 2002;105:595-601.

75. Colucci WS. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2002;343:246-53.

76. Mills RM, LeJemtel TH, Horton DP. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol 1999;34:155-62.

77. Publication Committee for the VMAC Investigators: intravenous nesiritide vs nitroglicerin for treatment of decompensated heart failure: a randomized controlled trial. JAMA 2002;287:1531-40.